Effects of Sulforaphane on Cognitive Function in Patients With Frontal Brain Damage
Effects of Sulforaphane on Cognitive Function in Patients With Frontal Brain Damage: Study Protocol for a Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: Zhixiong Liu
- Phone Number: +8615874290600
- Email: zhixiongliu@csu.edu.cn
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-65 years old
- Focal lesions were confined to the frontal brain, which is verified by CT or MRI
- Clinical diagnosis of Cognitive deficits using the Chinese version of the Montreal Cognitive Assessment (MoCA-C) with scores < 26 will be assessed as having cognitive deficits (<25 for patients educated <12 years)
- be adherent to the continued sulforaphane treatment medication
Exclusion Criteria:
- Previous history of cognitive impairment
- Brain MRI indicating damage was not restricted to the frontal lobe.
- Inability to cooperate with cognitive testing for disturbance of consciousness or mental disorder
- Pregnancy or maternal lactation
- Life expectancy < 3 months
- CO poisoning, autoimmune encephalitis, intracranial infection, or other types of diffuse intracranial disease.
- plan to receive radiotherapy during the trial period
- Laboratory examination showing liver and kidney insufficiency or other severe complications; the presence of diseases which may interfere with the results of the evaluation
- Involvement in other trials 1 month prior to the start of the trial or during the trial period
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: sulforaphane
To evaluate the effect of sulforaphane treatment on the cognitive deficits of patients with frontal brain damage
|
To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
|
|
PLACEBO_COMPARATOR: placebo
To evaluate the effect of sulforaphane treatment on the cognitive deficits of patients with frontal brain damage
|
To evaluate the effects of sulforaphane on the cognitive improvement of patients with frontal brain damage
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes from baseline cognitive tests scores at 3 months
Time Frame: Week 1 and week 12.
|
The battery of cognitive tests include different domains of cognitive tests, higher scores indicates better cognition.
|
Week 1 and week 12.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
the resting state MRI (rsMRI)
Time Frame: Week 0 and 12.
|
It can be served as a powerful tool to map networks of "functional connectivity" in the brain even in the absence of task activation or stimulation.
|
Week 0 and 12.
|
|
T1-weighted spin-echo MRI
Time Frame: Week 0, 4, and 12.
|
It can be used as outcome measures in therapeutic trials
|
Week 0, 4, and 12.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 202001005
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.